Biotest France’s Olivier Samama discusses their recent re-entry into France, their focus on homecare treatment, and their expertise in fractionation and plasma derived products.
What are the objectives and goals you have been given by Dr Bernhard Ehmer and what exactly has happened in building this affiliate these last two years? How much progress had been made?
I joined the company about three years ago with Dr. Schultz, former CEO of Biotest. At the time, he wanted to incorporate all the core countries in Europe into the Biotest Group and France was the last European affiliate missing. Dr. Schultz had the vision to enter into the French market first before launching new generation and innovative drugs.
France is a good candidate to test and sell new products as one of the most innovative global pharmaceutical markets.
